NDC Compounded Drug 26436-5608-2 Semaglutide
Injection Subcutaneous
Compounded Drug Product Information
NDC Crossover Products Matching Semaglutide
NDC crossover of Semaglutide with NDC 26436-5608 a human compounded drug with other similar products matching the same substance name (Semaglutide) and the same administration route (subcutaneous) or dosage form (injection).
NDC | Proprietary Name | Non-Proprietary Name | Package Desc | Dosage Form | Route Name | Company Name |
---|---|---|---|---|---|---|
54288-826-01 | Semaglutide Injection, 1 Mg/ml | Semaglutide Injection, 1 Mg/ml | 1143 mL in 1 VIAL | Injection | Subcutaneous | Bpi Labs Llc |
54288-827-01 | Semaglutide Injection, 5 Mg/2 Ml (2.5 Mg/ml) | Semaglutide Injection, 5 Mg/2 Ml (2.5 Mg/ml) | 266263 mL in 1 VIAL | Injection | Subcutaneous | Bpi Labs Llc |
54288-831-01 | Semaglutide Injection, 12.5 Mg/2.5 Ml (5 Mg/ml) | Semaglutide Injection, 12.5 Mg/2.5 Ml (5 Mg/ml) | 14969 mL in 1 VIAL | Injection | Subcutaneous | Bpi Labs Llc |
81483-0045-4 | Semaglutide | Semaglutide | 4 SYRINGE, GLASS in 1 TRAY > .05 mL in 1 SYRINGE, GLASS (81483-0045-1) | Injection | Subcutaneous | Tailstorm Health Inc |
81483-0049-4 | Semaglutide | Semaglutide | 4 SYRINGE, GLASS in 1 TRAY > .3 mL in 1 SYRINGE, GLASS (81483-0049-1) | Injection | Subcutaneous | Tailstorm Health Inc |
Frequently Asked Questions
What is the NDC number assigned to Semaglutide?
Semaglutide was assigned by its manufacturer with NDC product code 26436-5608. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.
Which are the NDC package codes for Semaglutide?
The NDC package code 26436-5608-2 was assigned to a 2 mL in 1 VIAL, MULTI-DOSE of semaglutide administered subcutaneous via injection.
Who manufactures this product?
Semaglutide is manufactured by an outsourced facility and labeled by Hybrid Pharma. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.
Which are the NDC crossover matchings for this product?
We found 5 matching products that have the same substance, dosage form and administration route. The matching products are manufactured by BPI Labs LLC and Tailstorm Health INC with NDC product codes 54288-826-01, 54288-827-01, 54288-831-01, 81483-0045-4 and 81483-0049-4.